Skip to main content
OpenTrials
Completed

NCT Number: NCT02394730

Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints

ADVICE is a randomised, international, double-blind, placebo-controlled trial. The purpose of the ADVICE study is to compare the safety and efficacy of vorapaxar in reducing d-dimer expression and markers of cellular immune activation over a period of 12 weeks among people with HIV infection who are successfully treated with combination antiretroviral therapy containing an HIV integrase inhibitor. A secondary objective of the study will be to demonstrate that following cessation of vorapaxar in patients with well controlled HIV replication there will be an increase in the levels of d-dimer over a 6 week period. 60 participants from 4 clinical sites in Australia and the USA will be recruited and followed for a minimum of 18 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

St Vincent's Hospital, Darlinghurst, New South Wales, Australia

Loading trial locations.

About this study

Consenting participants will be screened and within 14 days randomly allocated to receive either vorapaxar (2.5mg) or matched placebo once daily for 12 weeks (phase 1). Participants will be seen one week after randomisation and then at weeks 4, 8 and 12 (phase 1). At the week 12 visit, patients will not be dispensed any study treatment. In phase 2 all study treatment will stop for 6 weeks. At week 18 patients will be seen for a final study visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • HIV-1 positive by licensed diagnostic test
  • aged ≥40 years
  • plasma HIV RNA <50 copies/mL for at least 24 weeks
  • screening CD4+ cell count > 50 cells/mm3
  • treated for at least 12 weeks with a suppressive regimen of combination antiretroviral therapy that does not include HIV protease inhibitors and/or NNRTIs (except rilpivirine)
  • plasma d-dimer >200ng/mL (>0.2μg/mL or >0.2mg/L) fibrinogen equivalent units or >100ng/mL (>0.1 μg/mL or >0.1mg/L) d-dimer units in the absence of established cause (deep vein thrombosis/embolism)
  • provision of written informed consent

Exclusion criteria

  • Absolute neutrophil count (ANC) <1000 cells/μL
  • hemoglobin <10.0 g/dL
  • platelet count <75,000 cells/μL
  • AST and/or ALT >2.5 x ULN
  • estimated glomerular filtration rate <30mL/min/1.73m2 ) using CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation
  • history of myocardial infarction or unstable atherosclerotic disease
  • history of ischemic stroke or transient ischaemic attack (TIA)
  • active peptic/duodenal ulcer or other bleeding disorder within the previous 12 months
  • intent to have surgery within the 6 month period after randomisation
  • current use of aspirin or P2Y12 antiplatelet therapy
  • use of anticoagulants, (eg. heparin or warfarin), fibrinolytic therapy, chronic use (more than 5 consecutive days) of nonsteroidal anti-inflammatory drugs (NSAIDS), strong CYP3A4 inhibitors or inducers. See Manual of Operations for full list of medications to avoid.
  • participants unlikely to be able to remain in follow-up
  • pregnant or nursing mothers
  • in the clinical judgement of the investigator, participation in this trial is deemed inappropriate as this may conflict with the well-being of the participant.

Treatment and study plan

Vorapaxar

Drug

2.5mg of vorapaxar taken orally once daily for 12 weeks

Other names: Zontivity

Placebo

Drug

Sugar pill taken orally once daily for 12 weeks

Other names: sugar pill

Primary outcomes

  1. Mean Percent Change From Baseline for D-dimer (ng/mL) to the Average of Weeks 8 and 12

    Time frame: at week 8 and week 12

    Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transforming the log10 difference to obtain percentage change from baseline.

Secondary outcomes

  1. Number of Participants in Each Treatment Group With Plasma HIV-1 RNA <50 Copies/mL

    Time frame: at week 18

    Number of participants in each treatment group with plasma HIV-1 RNA <50 copies/mL at week 18

  2. Mean Change From Baseline to Week 12 in CD4+ Cell Counts

    Time frame: at week 12

    Mean of week 12 CD4+ cell count minus mean of week 0 CD4+ cell count

  3. Mean Change From Baseline to Week 12 in CD8+ Cell Counts

    Time frame: at week 12

    Mean of week 12 CD8+ cell count minus mean of week 0 CD4+ cell count

  4. Number of Patients in Each Treatment Group With D-dimer <165ng/mL at Week 12

    Time frame: week 12

    Number of patients in each treatment group with d-dimer <165ng/mL at week 12

  5. Number of Patients in Each Treatment Group With D-dimer > or Equal to 165ng/mL at Week 18

    Time frame: week 18

    Number of patients in each treatment group with d-dimer > or equal to 165ng/mL at week 18

  6. Mean Change From Baseline in log10 D-Dimer

    Time frame: at week 18

    Differences between treatment groups in mean change from week 0 log10 d-dimer to week 18

  7. Mean Change From Baseline in log10 Hs-CRP at Week 18

    Time frame: at week 18

    Differences between treatment groups in mean change from baseline log10 hs-CRP to week 18. ie Week 18 log10 hs-CRP minus week 0 log10 hs-CRP

  8. Percent Change From Baseline Hs-CRP (ug/mL) to the Average of Week 8 and Week 12

    Time frame: week 8 and 12

    Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transformed the log10 difference to obtain percentage change from baseline.

  9. Mean Percent Change From Baseline IL-6 (pg/mL) to the Average of Week 8 and Week 12

    Time frame: at week 8 and week 12

    Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transformed the log10 difference to obtain percentage change from baseline.

  10. Differences Between Treatment Groups in Mean Change From Baseline log10 IL-6

    Time frame: at week 18

    Differences between treatment groups in mean change from baseline log10 IL-6 at week 18

  11. Total Number of Participants With BARC Type 1, 2, 3, 4, or 5 Bleeding Episodes

    Time frame: at week 18

    Bleeding Academic Research Consortium (BARC) Definitions for Bleeding Events Type 1 -bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a healthcare professional Type 2 - overt, actionable sign of haemorrhage (eg, more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: (1) requiring nonsurgical, medical intervention by a healthcare professional, (2) leading to hospitalization or increased level of care, or (3) prompting evaluation Type 3- Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid) Type 4 - Coronary Artery Bypass Graft procedure-related bleeding Type 5 -

  12. Total Number of Participants With Any SAE Between Baseline and Week 18

    Time frame: week 18

    Total number of participants with any SAE between baseline and week 18

  13. Total Number of Participants With Any AE Between Baseline to Week 18

    Time frame: week 18

    Total number of participants with any AE between week 0 to week 18

  14. Changes From Baseline in Renal Function Measured by the CKD-EPI Estimate of Creatinine Clearance at Week 12

    Time frame: at week 12

    Changes from baseline in renal function measured by the CKD-EPI estimate of creatinine clearance at week 12

Sponsors and collaborators

Lead sponsor

Kirby Institute

Other Gov

Collaborators

  • Merck Sharp & Dohme LLC
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • University of Melbourne
  • University of Minnesota

Registry information

Official study title

A Double Blind Randomised Comparison of Vorapaxar Versus Placebo for the Treatment of HIV Associated Inflammation and Coagulopathy in Patients With Well Controlled HIV Replication

Acronym: ADVICE

Important dates

Study start
2015
Primary completion
2017
Study completion
2018
First posted
Mar 20, 2015
Registry last updated
Mar 6, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.